The anticancer effects of pharmacological inhibition of autophagy in acute erythroid leukemia cells

Anticancer Drugs. 2018 Nov;29(10):944-955. doi: 10.1097/CAD.0000000000000668.

Abstract

Although recent studies have reported different aspects of autophagy, from pro-survival to pro-death roles of this process in malignant cells, the underlying mechanisms by which autophagy inhibitors contribute toward the induction of programmed cell death in cancerous cells are still unclear. In the present study, we have attempted to explore some of the molecular features of pharmacological inhibition of autophagy in TF-1 cells (an acute erythroid leukemia model). Our findings indicated that ara-C induces autophagy (with alteration of LC3B, p62, and Beclin-1) in the cells; however, targeting autophagy by 3-methyladenine and chloroquine significantly increased caspase-dependent apoptosis and the sub-G1 compartment in ara-C-treated cells. Moreover, cell cycle analysis showed that 3-MA, as an early-stage autophagy inhibitor, could elevate the cell population in the G0/G1 cell cycle phase, which was associated with upregulation of p21 and p27 expressions. Interestingly, autophagy inhibition was also accompanied by downregulation of c-Myc gene and protein expression levels and upregulated levels of Bax and Bak gene expressions. In addition, following inhibition of autophagy, the levels of tumor-suppressive miRNA (i.e. miR-204) increased, whereas the values of oncogenic miRNAs (including miR-21, miR-221, miR-30a, and miR-17) decreased. Overall, our experiments indicate that autophagy inhibitors (especially chloroquine) seem to be promising agents for combination therapy in acute erythroid leukemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Antimetabolites, Antineoplastic / pharmacology*
  • Autophagy / drug effects*
  • Cell Line, Tumor
  • Chloroquine / pharmacology
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclin-Dependent Kinase Inhibitor p27 / genetics
  • Cytarabine / pharmacology*
  • Down-Regulation / genetics
  • G1 Phase / drug effects
  • Humans
  • Leukemia, Erythroblastic, Acute / drug therapy*
  • MicroRNAs / genetics
  • Resting Phase, Cell Cycle / drug effects
  • Up-Regulation / genetics

Substances

  • Antimetabolites, Antineoplastic
  • Cyclin-Dependent Kinase Inhibitor p21
  • MicroRNAs
  • Cytarabine
  • Cyclin-Dependent Kinase Inhibitor p27
  • 3-methyladenine
  • Chloroquine
  • Adenine